Ascendis Pharma A/S (NASDAQ:ASND - Free Report) - Investment analysts at Leerink Partnrs raised their FY2024 earnings per share estimates for shares of Ascendis Pharma A/S in a research note issued to investors on Monday, January 20th. Leerink Partnrs analyst J. Schwartz now anticipates that the biotechnology company will post earnings of ($6.44) per share for the year, up from their previous estimate of ($6.50). The consensus estimate for Ascendis Pharma A/S's current full-year earnings is ($7.12) per share. Leerink Partnrs also issued estimates for Ascendis Pharma A/S's Q4 2024 earnings at ($0.26) EPS, Q1 2025 earnings at ($1.90) EPS, Q2 2025 earnings at ($1.81) EPS, Q3 2025 earnings at ($1.74) EPS, Q4 2025 earnings at ($1.66) EPS, FY2025 earnings at ($7.12) EPS and FY2026 earnings at ($2.00) EPS.
A number of other equities research analysts have also issued reports on ASND. Wedbush reaffirmed an "outperform" rating and set a $181.00 target price on shares of Ascendis Pharma A/S in a report on Friday, November 15th. TD Cowen dropped their price objective on shares of Ascendis Pharma A/S from $160.00 to $153.00 and set a "buy" rating for the company in a research note on Friday, November 15th. JPMorgan Chase & Co. decreased their target price on shares of Ascendis Pharma A/S from $180.00 to $174.00 and set an "overweight" rating on the stock in a research note on Wednesday, October 23rd. Stifel Nicolaus upped their price target on Ascendis Pharma A/S from $200.00 to $207.00 and gave the company a "buy" rating in a research report on Friday, November 15th. Finally, UBS Group initiated coverage on Ascendis Pharma A/S in a research report on Tuesday, January 7th. They set a "buy" rating and a $196.00 price objective on the stock. Two research analysts have rated the stock with a hold rating and thirteen have given a buy rating to the stock. Based on data from MarketBeat, the stock currently has an average rating of "Moderate Buy" and an average target price of $192.07.
Read Our Latest Stock Analysis on ASND
Ascendis Pharma A/S Stock Performance
Shares of ASND traded down $5.24 during trading hours on Wednesday, hitting $125.82. 551,934 shares of the stock were exchanged, compared to its average volume of 462,502. The stock's 50-day moving average price is $133.19 and its two-hundred day moving average price is $133.34. Ascendis Pharma A/S has a 12-month low of $111.09 and a 12-month high of $161.00. The company has a market cap of $7.64 billion, a price-to-earnings ratio of -15.57 and a beta of 0.65.
Institutional Trading of Ascendis Pharma A/S
Hedge funds and other institutional investors have recently made changes to their positions in the company. Wilmington Savings Fund Society FSB purchased a new position in Ascendis Pharma A/S in the third quarter valued at about $30,000. Groupama Asset Managment purchased a new stake in shares of Ascendis Pharma A/S in the third quarter valued at $60,000. Blue Trust Inc. increased its position in Ascendis Pharma A/S by 540.5% during the 4th quarter. Blue Trust Inc. now owns 506 shares of the biotechnology company's stock worth $76,000 after purchasing an additional 427 shares in the last quarter. GAMMA Investing LLC raised its stake in Ascendis Pharma A/S by 58.0% in the 4th quarter. GAMMA Investing LLC now owns 583 shares of the biotechnology company's stock valued at $80,000 after purchasing an additional 214 shares during the last quarter. Finally, Signaturefd LLC lifted its holdings in Ascendis Pharma A/S by 13.2% in the 3rd quarter. Signaturefd LLC now owns 686 shares of the biotechnology company's stock valued at $102,000 after purchasing an additional 80 shares in the last quarter.
About Ascendis Pharma A/S
(
Get Free Report)
Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates.
Further Reading
Before you consider Ascendis Pharma A/S, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Ascendis Pharma A/S wasn't on the list.
While Ascendis Pharma A/S currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Which stocks are likely to thrive in today's challenging market? Click the link below and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
